Bevacizumab (Anti-VEGFA)

Name: Bevacizumab (Anti-VEGFA)
Brand: MedChemExpress
SKU: HY-P9906A
Rating: 5.0 (51 reviews)

Cat. No.: HY-P9906A Purity: 99.07%: Data Sheet
COA

SDS

FAQs
Technical Support

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

For research use only. We do not sell to patients.

CAS No. : 216974-75-3

Size	Stock	Quantity
Free Sample (100 μg)	Apply Now
Free Sample (100 μg)	Apply Now
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 51 publication(s) in Google Scholar

Other Forms of Bevacizumab (Anti-VEGFA):

Bevacizumab In-stock

51 Publications Citing Use of MCE Bevacizumab (Anti-VEGFA)

IHC

In Vivo Efficacy Study

Cell Migration/Invasion Assay

Others

Flow Cytometry

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 24;10(1):417. [Abstract]; Treatment of PC9-BM LCN2-high BM-bearing mice with SH4-54 (10 mg/kg, intraperitoneally, twice per week), Bevacizumab (10mg/kg, intraperitoneally, twice per week), or a combination of both significantly suppressed tumor progression and prolonged overall survival.

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]; Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]; Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45⁺ cells), anti-CD68/CD80-stained macrophages (gated on CD45⁺ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45⁺ Lin-1^- T cells), and anti-CD3/CD8-stained T cells (gated on CD45⁺ cells) in tumor tissues after different treatments (n = 5 independent mice).

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]; Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) significantly reversed the upregulatory effect of TQHXD and HXHY on VEGFA protein in MCAO rats.

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]; Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) effectively antagonized the inherent pro-angiogenic effects of TQHXD and HXHY in MCAO rats.

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: J Clin Oncol. 2024 Oct 30:JCO2401266. [Abstract]; Tumor-bearing mice were treated with vehicle, Onvansertib, and/or Bevacizumab (intraperitoneally, 5 mg/kg for SW620 and HCT116, 1 mg/kg for LoVo, twice a week) for 30-33 days.

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]; Transwell assays showing that Bevacizumab (200 ng/mL, 12 h) failed to inhibit the migration of HUVECs treated with recombinant PTN protein. Unpaired t test; **, P < 0.01; ****, P <0.0001.

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]; Tube formation assays showed that Bevacizumab (200 ng/mL) failed to inhibit the tube formation of HUVECs induced by recombinant PTN protein.Unpaired t test; ***, P <0.001; ****, P <0.0001.

: Bevacizumab (Anti-VEGFA) purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):619-638. [Abstract]; VEGFA IHC staining in control and ATL-I (80 μM or 160 μM)-treated Matrigel plugs. Quantification of vegfa-positive cells. Scale bar: 100 μm. In the present set of experiments, Bevacizumab (50 ng/ml) was used as the positive control.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All VEGFR Isoform Specific Products:

View All Isoforms

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

Biological Activity
Purity & Documentation
References
Customer Review

Description

Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity^[1]^[2].

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

VEGF-A

In Vitro

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2^[1]. Experimental analysis shows that the EC₅₀ of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC₅₀ value of 0.047±0.0081 μg/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Gene ID

7422 [NCBI]

Accession

P15692

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

146.56 kDa

CAS No.

216974-75-3

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Bevacizumab (Anti-VEGFA)]

Shipping

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa

Biological Activity

Flow cytometric analysis of 1X10⁶ HeLa cells with Bevacizumab (HY-P9906A, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC₅₀ for this effect is 5.34 ng/mL.

Purity & Documentation

Purity: 99.07%

Select Batch:

Data Sheet (261 KB) SDS (251 KB)

COA (232 KB) SDS-PAGE (94 KB) SEC-HPLC (121 KB)

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504. [Content Brief]

[2]. Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435. [Content Brief]